Dianthus Therapeutics (DNTH) return on invested capital (ROIC)
Only 2 fiscal years of return on invested capital are on record here for Dianthus Therapeutics (DNTH); a history needs at least 3. Figures as of 17 Nov 2026, 21:14 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Return on invested capital, fiscal 2025
- -155.3%
- Change on fiscal 2024
- −53.1 pts
- Fiscal years on record
- 22024–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.
Not enough data
A history of return on invested capital needs at least 3 fiscal years; 2 are on record here for Dianthus Therapeutics. Nothing is estimated to fill the gap. What is on record is in the table below.
Dianthus Therapeutics return on invested capital (ROIC), year by year
| Fiscal year | Return on invested capital | Change | Year ended |
|---|---|---|---|
| 2025 | -155.3% | 53.1 pts down | |
| 2024 | -102.2% | — |
Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Return on invested capital is operating income after tax divided by the capital in the business — debt plus equity minus cash — using the company's own tax rate where it is plausible and 21% otherwise, and shown only for the fiscal years in which cash is counted one way.
How to read it
It measures how well the business turns capital into profit whoever supplied it; a figure above the cost of that capital, roughly 8–10%, means growth creates value.
Return on invested capital at health care companies of similar size
| Company | Return on invested capital | Fiscal year |
|---|---|---|
| LivaNova LIVN | 15.8% | 2025 |
| Dianthus Therapeutics DNTH | -155.3% | 2025 |
| MiniMed Group MMED | -3.6% | 2026 |
| Adaptive Biotechnologies ADPT | -63.6% | 2025 |
| Heartflow HTFL | -34.7% | 2025 |
The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.
Dianthus Therapeutics, figure by figure
- Dianthus Therapeutics market cap
- Dianthus Therapeutics revenue
- Dianthus Therapeutics earnings
- Dianthus Therapeutics earnings per share (EPS)
- Dianthus Therapeutics P/E ratio
- Dianthus Therapeutics P/S ratio
- Dianthus Therapeutics P/B ratio
- Dianthus Therapeutics free cash flow
- Dianthus Therapeutics operating margin
- Dianthus Therapeutics dividend
- Dianthus Therapeutics shares outstanding
- Dianthus Therapeutics total debt
- Dianthus Therapeutics cash on hand
- Dianthus Therapeutics total assets
- Dianthus Therapeutics return on equity (ROE)
Dianthus Therapeutics (DNTH) overview: price, valuation and scorecardAll health care companies by market value
Dianthus Therapeutics return on invested capital (ROIC): questions and answers
How is Dianthus Therapeutics's return on invested capital calculated?
Return on invested capital is operating income after tax divided by the capital in the business — debt plus equity minus cash — using the company's own tax rate where it is plausible and 21% otherwise, and shown only for the fiscal years in which cash is counted one way.
Fiscal years are named for the calendar year they end in.
Learn: return on invested capital (ROIC)
All stocks guides →- Return on invested capital (ROIC) vs ROE and ROA
Return on invested capital (ROIC) is after-tax operating profit divided by the money tied up in the business: debt plus equity, less cash. A company earning $15 million after tax on $100 million of invested capital has a 15% ROIC. Unlike return on equity, it does not rise just because a company borrows more.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Dianthus Therapeutics (DNTH) return on invested capital (ROIC)”, data as of 17 November 2026. https://funkfolio.com/stock/DNTH/roic
Underlying data: the company's filings with the SEC and Yahoo Finance.